Prognostic Significance of Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using <sup>131</sup>I-Rituximab - Concepedia

Concepedia

Publication | Closed Access

Prognostic Significance of Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using <sup>131</sup>I-Rituximab

14

Citations

24

References

2013

Year

Ilhan Lim, Joon Yeun Park, Hye Jin Kang, Jae Pil Hwang, Seung‐Sook Lee, Kyeong Min Kim, Tae Hyun Choi, Sung Hyun Yang, Byung Il Kim, Chang Woon Choi,

Acta Haematologica

Abstract

SUVmax and tumor size determined by a pretreatment ¹⁸F-FDG PET/CT result as significant predictors of OS in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma treated by RIT.

References

	Year	Citations

Page 1